(Q46654013)

24 December 2017

title

ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere (English)

1 reference

24 December 2017

1 reference

Tomasz M Beer

1

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

published in

BJU International

1 reference

24 December 2017

volume

96

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

508-513

1 reference

24 December 2017

Vitamin D in preventive medicine: are we ignoring the evidence?

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Intermittent chemotherapy in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05675.X

10.1111/J.1464-410X.2005.05675.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017